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C3aR and C5aR1-driven beta-arrestin recruitment. Activa-
tion of C3aR and C5aR1 potentiated glucose-induced insulin 
secretion from human and mouse islets, increased  [Ca2+]i 
and ATP generation, and protected islets against apoptosis 
induced by a pro-apoptotic cytokine cocktail or palmitate.
Conclusions Our observations demonstrate a functional 
link between activation of components of the innate immune 
system and improved β-cell function, suggesting that low-
level chronic inflammation may improve glucose homeosta-
sis through direct effects on β-cells.
Keywords G protein-coupled receptors · Islets of 
Langerhans · Insulin secretion · Alternative complement 
pathway · C3aR · C5aR1
Introduction
Type 2 diabetes (T2D) is a chronic disease characterised by 
increased insulin resistance and decreased β-cell mass and 
function [1]. The complement system, an important compo-
nent of the innate immune system, consists of several small, 
inactive serum precursor proteins that are mainly synthe-
sised by the liver. Upon activation, proteases cleave the pre-
cursor C3 and C5 into the active complement fragments C3a, 
C3b, C5a and C5b. These proteolytic cleavage cascades of 
intact C3 and C5 are responsible for the formation of a mem-
brane attack complex and activation of an adaptive immune 
response [2]. The C3a and C5a peptide fragments that are 
generated, also known as anaphylatoxins, are responsible 
for production of local inflammatory responses and they 
exert at least part of their biological effects via activating 
the G protein-coupled receptors (GPCRs) C3aR, C5aR1 and 
C5aR2 that are encoded by the C3AR1, C5AR1 and C5AR2 
genes [3–5].
Abstract 
Aims Complement components 3 and 5 (C3 and C5) play 
essential roles in the complement system, generating C3a 
and C5a peptides that are best known as chemotactic and 
inflammatory factors. In this study we characterised islet 
expression of C3 and C5 complement components, and the 
impact of C3aR and C5aR1 activation on islet function and 
viability.
Materials and methods Human and mouse islet mRNAs 
encoding key elements of the complement system were 
quantified by qPCR and distribution of C3 and C5 proteins 
was determined by immunohistochemistry. Activation of 
C3aR and C5aR1 was determined using DiscoverX beta-
arrestin assays. Insulin secretion from human and mouse 
islets was measured by radioimmunoassay, and intracellu-
lar calcium  ([Ca2+]i), ATP generation and apoptosis were 
assessed by standard techniques.
Results C3 and C5 proteins and C3aR and C5aR1 were 
expressed by human and mouse islets, and C3 and C5 were 
mainly localised to β- and α-cells. Conditioned media from 
islets exposed for 1 h to 5.5 and 20 mM glucose stimulated 
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In addition to their roles in innate immunity, an emerg-
ing body of literature suggests that intact C3 and C5 com-
plement proteins, and the cleaved C3a and C5a peptides, 
are important in regulating whole body metabolism, energy 
homeostasis and the pathogenesis of diabetes and metabolic 
syndrome. For example, C3/C3a are positively associated 
with the incidence of diabetes [6–8] and insulin resistance 
[9, 10], and C5/C5a contribute to adipose tissue inflam-
mation and insulin resistance [11, 12]. Moreover, C3a and 
C5a receptor antagonists have been reported to inhibit diet-
induced obesity, metabolic dysfunction, and adipocyte and 
macrophage signalling in vivo in the rat [13]. In contrast, 
the adipokine adipsin (also known as complement factor D 
(CFD)), an adipose tissue-derived protease required for the 
generation of the C3 convertase, improves islet β-cell func-
tion by increasing conversion of circulating C3 into C3a 
[14]. Thus, studies to date implicate intact C3 and C5 and 
their peptide fragments in metabolic dysregulation through 
induction of insulin resistance, while a report with adipsin 
[14] suggests beneficial effects of C3a on β-cells. Since very 
little is currently known about the direct effects of C3/C3a 
and C5/C5a on β-cell function, the aims of this study were 
to determine the mRNA and protein expression of C3/C3a 
and C5/C5a in islets, and identify the effects of C3aR and 
C5aR1 activation on human and mouse islet secretory func-
tion and viability.
Materials and methods
Reagents
The C3aR agonist sc-214644, C3aR antagonist SB 290157 
and C5aR1 agonist 65121-ANA were from Cambridge Bio-
science (Cambridge, UK). The C5aR1 antagonists PMX 
205 and W 54011 were from Tocris Bioscience (Bristol, 
UK). Intact C3 and C5 proteins were from Millipore (UK) 
Limited (Hertfordshire, UK), C3 antibody was from LifeS-
pan BioSciences, Inc. (Seattle, USA) and C5 antibody was 
from Insight Biotechnology (Wembley, UK). The glucagon 
antibody was from Sigma-Aldrich (Dorset, UK), insulin 
antibody from DAKO UK Ltd. (Ely, UK) and somatostatin 
antibody from Abcam plc (Cambridge, UK). Anti-rabbit, 
anti-guinea pig, anti-rat and anti-mouse secondary antibod-
ies were from Jackson ImmunoResearch (Suffolk, UK). 
DAPI nucleic acid stain was from Thermo Fisher Scien-
tific (Northumberland, UK). C3aR and C5aR1 beta-arrestin 
assays were from DiscoverX Corporation, Ltd. (Birming-
ham, UK). Recombinant murine TNFα, IFNγ and IL-1β 
were from PeproTech EC Ltd. (London, UK). Caspase 3/7 
assay kits and CellTiter-Glo® 3D assay kits were from Pro-
mega UK (Southampton, UK). The TaqMan RT-PCR kit 
was from Thermo Fisher Scientific (Loughborough, UK) 
and QuantiTect SYBR Green qPCR kits with QuantiTect 
qPCR assays were from Qiagen Ltd. (Manchester, UK). All 
other chemicals were from Sigma-Aldrich or Thermo Fisher 
Scientific.
Human and mouse islet isolation and culture
Islets were isolated from 10–12-week-old male Crl:CD1 
(ICR) mice (Charles River), by collagenase digestion of the 
exocrine pancreas [15]. Human islets were isolated from 
heart-beating non-diabetic donors, with appropriate ethical 
approval, at the King’s College London Human Islet Isola-
tion Unit [16]. Islets were maintained overnight at 37 °C in 
culture medium supplemented with 5.6 mM glucose, 10% 
FCS, 2 mM glutamine and penicillin–streptomycin (100 U/
mL, 0.1 mg/mL) before experimental use.
RNA extraction and quantitative real‑time PCR
A modified TRIzol protocol [17] was used to extract total 
RNA from human and mouse islets, and RNA was converted 
into cDNA using the TaqMan RT-PCR kit. Real-time PCR 
was performed using a LightCycler480 and gene expres-
sion relative to the house-keeping genes ACTB, GAPDH, 
PPIA, TBP and TCRF was carried out using QuantiTect 
qPCR assays (Supplementary Table 1), as described else-
where [18, 19]. All complement and reference gene primer 
efficiency (E) [20] values were in the range of 1.85–2.15. For 
all complement and reference gene quantifications, template 
cDNAs were diluted in such a way that all quantified genes 
returned Ct values <30. Genes that expressed <0.001% of 
the mean level of the house keeping genes were considered 
to be present only at trace level, as their mRNA expression 
was below the lower limit of linear quantification for the 
QuantiTect primer assays.
Immunohistochemistry
C3 and C5 complement protein expression by mouse and 
human pancreas was determined using rabbit anti-C3 and 
anti-C5 antibodies (both at 1:20) and Alexa  Fluor® 488 
anti-rabbit secondary antibody (1:150). C3 and C5 protein 
localisation in islet cells was probed by co-staining with 
guinea pig anti-insulin (1:200), mouse anti-glucagon (1:100) 
and rat anti-somatostatin (1:50) and species-specific Alexa 
 Fluor® 594 secondary antibodies (all at 1:200). Nuclei were 
detected using DAPI (1:500). Specificity of immunofluo-
rescent staining was confirmed by staining consecutive sec-
tions in the absence of primary antibody but with secondary 
antibody alone (at 1:150).
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Beta‑arrestin assays
Induction of beta-arrestin recruitment for C3aR and C5aR1 
was determined using  PathHunter® eXpress C3aR U2OS 
and C5aR1 CHO-K1 GPCR beta-arrestin kits. In brief, 8000 
C3aR U2OS or C5aR1 CHO-K1 cells were dispensed into 
wells of the 96-well plate and incubated for 48 h (37 °C, 5% 
 CO2). These cells were then exposed for 90 min to C3aR 
and C5aR1 agonists, intact C3 or C5 complement proteins 
or conditioned medium obtained from mouse islets that had 
been incubated for 1 h (37 °C, 5%  CO2) in a physiological 
salt solution in the absence of glucose or in medium sup-
plemented with 5.5 or 20 mM glucose. Beta-arrestin activ-
ity driven by C3aR and C5aR1 was quantified according to 
the manufacturer’s instructions using a luminescence plate 
reader on an unfiltered, full-range luminescence setting.
Static insulin secretion
Groups of five mouse and human islets were incubated for 
1 h in a physiological salt solution [21], either in the absence 
or presence of 1 µM C3aR or C5aR1 agonists or antagonists 
or with 100 nM intact C3 or C5 complement proteins (alone 
or in combination with 1 µM of the respective antagonist). 
In some experiments insulin secretion was quantified in the 
presence of increasing concentrations (1 nM–10 µM) of 
C3aR or C5aR1 antagonists SB 290157, PMX 205 or W 
54011. Insulin secreted into the supernatant was quantified 
by radioimmunoassay, essentially as described elsewhere 
[22].
Dynamic insulin secretion
The effects of agonists and antagonists at C3aR or C5aR1 on 
dynamic insulin secretion from human islets were assessed 
using a temperature-controlled perifusion system [23, 24]. 
Briefly, 50 human islets were transferred to chambers con-
taining 1 μm filters and perifused (37 °C, 0.5 mL/min) 
with a salt solution [21] containing 2 or 20 mM glucose in 
the absence or presence of C3aR or C5aR1 agonists and/
or antagonists. Perifusate samples were collected at 2-min 
intervals and secreted insulin was quantified by radioim-
munoassay [22].
ATP
Islet ATP production, which is a marker of islet metabo-
lism, was quantified using the CellTiter-Glo® 3D assay. 200 
mouse islets were pre-incubated for 1 h in a salt solution [21] 
supplemented with 2 mM glucose then groups of 3 islets 
were incubated in 96-well plates in the absence or presence 
of intact C3 or C5 complement proteins or C3aR or C5aR1 
agonists or antagonists. Cells were lysed and ATP was quan-
tified according to the manufacturer’s instructions.
Intracellular calcium  ([Ca2+]i)
Groups of approximately 100,000 dispersed mouse islet 
cells were seeded onto glass coverslips, maintained in cul-
ture overnight then loaded with 5 μM Fura-2 AM for 30 min. 
Cells were perifused (37°C, 1 mL/min) with a physiological 
salt solution in the absence or presence of test agents and 
real-time changes in  [Ca2+]i were determined by illuminat-
ing cells alternately at 340 and 380 nm, with emitted light 
being filtered at 510 nm.
Apoptosis
Mouse and human islet apoptosis was assessed in the pres-
ence or absence of C3aR or C5aR1 agonists and/or antag-
onists using the Caspase-Glo 3/7 assay according to the 
manufacturer’s instructions. Anti-apoptotic effects were 
evaluated following induction of apoptosis by either palmi-
tate (500 μM) or a cocktail of pro-apoptotic cytokines (25 U/
mL IL-1β; 1000 U/mL TNFα; 1000 U/mL IFNγ).
Statistical analysis
GraphPad Prism 5.0 (GraphPad Software, Inc) was used for 
statistical analysis. Data are presented as mean ± SEM and 
were analysed using ANalysis Of VAriance (ANOVA). Sta-
tistical significance was set at p values of <0.05 (*), <0.01 
(**), <0.001 (***), <0.0001 (****).
Results
Quantification of complement component mRNA 
expression in human and mouse islets
Human and mouse islets expressed similar levels of mRNAs 
encoding intact C3 and C5 complement proteins, with C3 
mRNA levels being approximately 20-fold higher than those 
of C5 (Fig. 1). The qPCR analysis also indicated that human 
and mouse islets expressed mRNAs encoding the receptors 
through which active C3a and C5a complement peptides 
exert their effects. Thus, C3aR mRNA was expressed at 
high levels in mouse islets and at low levels in human islets, 
whereas mRNA encoding C5aR1 was found at intermediate 
or low levels in human and mouse islets, respectively. C5a 
is also a ligand for C5aR2, but mRNA encoding this recep-
tor was below the lower limit of linear quantification for the 
QuantiTect primer assays in both human and mouse islets. 
Complement factor D (CFD), also known as adipsin, and 
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complement 2 (C2) help encoding complement cascade pro-
teins with C3 and C5 convertase activity [25], which cleave 
C3 and C5 to generate the active C3a and C5a peptides. Both 
CFD and C2 mRNAs were detectable at low levels in human 
and mouse islets (Fig. 1).
Immunohistochemical detection of C3 and C5 in mouse 
and human pancreas
Fluorescence immunohistochemical staining indicated that 
C3 was distributed throughout mouse (Fig. 2A) and human 
(Fig. 2B) islets. Co-staining with antibodies against insulin, 
glucagon and somatostatin demonstrated that C3 co-local-
ised with all three hormones, indicating that it is expressed 
by α-, β- and δ-cells (Fig. 2a, b, e, g). C5 was also detected 
in mouse (Fig. 2c) and human (Fig. 2d) islets, where it co-
localised primarily with insulin, and low expression of this 
complement protein was also detected in α- and δ-cells 
(Fig. 2c, d, f, h). C3 and C5 proteins were also expressed 
by exocrine cells in both mouse and human pancreas 
(Fig. 2a–d).
Quantification of C3aR and C5aR1 activation
DiscoverX beta-arrestin reporter cell assays indicated 
that commercially available selective agonists for C3aR 
(sc-214644) and C5aR1 (65121-ANA) induced concen-
tration-dependent activation of C3aR and C5aR1, with 
half-maximal activation at 804 nM sc-214644 and 292 nM 
65121-ANA, respectively (Fig. 3a, b). The agonists were, 
therefore, used at 1 μM for islet functional experiments to 
ensure robust activation of C3aR and C5aR1. Intact C3 and 
C5 complement proteins also stimulated C3aR- and C5aR1-
dependent beta-arrestin recruitment: C3 activated C3aR and, 
to a much lesser extent, C5aR1, whereas C5 only evoked 
beta-arrestin recruitment to C5aR1 (Fig. 3c, d).
Islet‑derived C3aR and C5aR1‑activating factors
Since our qPCR and immunohistochemical data indicated 
that islets express intact C3 and C5, the beta-arrestin assays 
were also used to determine whether factors capable of 
activating C3aR and C5aR1 were released from islets. Con-
ditioned media retrieved from mouse islets that had been 
incubated for 1 h stimulated C3aR (Fig. 4a) and C5aR1 
(Fig. 4b) beta-arrestin recruitment in a glucose concentra-
tion-dependent manner, while medium from islets that had 
been incubated in the absence of glucose did not activate 
the receptors.
Effects of modifying C3aR and C5aR1 activity 
on glucose‑induced insulin secretion
Exposure of mouse and human islets to C3aR (1  μM, 
sc-214644) and C5aR1 (1  μM, 65121-ANA) agonists 
resulted in significant potentiation of glucose-induced 
insulin secretion, and stimulatory effects were also 
observed when islets were incubated with intact C3 and C5 
(Fig. 5a–d). Potentiation of insulin secretion by intact C3 and 
C5 was reduced by co-incubation of islets with C3aR and 
C5aR1 antagonists, which also inhibited insulin secretion 
stimulated by 20 mM glucose alone (Fig. 5a–d). This inhi-
bition of glucose-stimulated insulin secretion by C3aR and 
C5aR1 antagonists was confirmed by constructing concen-
tration–response curves using mouse islets, which indicated 
half-maximal inhibition at ~45–80 nM of antagonists and 
maximal inhibition at 1 μM (Supplementary Figure 1A–C). 
Based on these results, antagonists were used in functional 
experiments at 1 µM to maximally inhibit C3aR and C5aR1. 
Time-resolved perifusion experiments with human islets 
confirmed the capacity of sc-214644 (Fig. 6a) and 65121-
ANA (Fig. 6b) to potentiate glucose-induced insulin secre-
tion. The elevation in insulin release with both agonists was 
rapid in onset and insulin secretion was significantly reduced 
in the presence of SB 290157 and PMX 205.
Effects of modifying C3aR and C5aR1 activity on islet 
ATP generation
Quantification of islet ATP generation indicated that C3aR 
activation with 1 μM sc-214644 significantly elevated ATP 
generation at 20 mM glucose, and similar effects were 
obtained following C5aR1 activation by 1 μM 65121-ANA 
(Fig. 7). Exposure of mouse islets to 100 nM intact C3 or 
C5 also significantly potentiated glucose-stimulated ATP 
production while C3aR and C5aR1 antagonists significantly 
inhibited ATP generation at 20 mM glucose (Fig. 7).
Fig. 1  Relative mRNA expression of complement receptors and pro-
teins by human and mouse islets. Data are presented as mean expres-
sion relative to the reference genes ACTB, GAPDH, PPIA, TBP and 
TFRC. T trace mRNA expression, C3aR complement receptor C3a, 
C5aR1 complement receptor C5a1, C5aR2 complement receptor 
C5a2, C3 complement component 3, C5 complement component 5, 
CFD complement factor D (adipsin), C2 complement  component 2, 
n = 3–4 individual human or mouse islet donors
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Fig. 2  Expression of C3 and 
C5 complement proteins by 
mouse and human pancreas. 
A–D Co-localisation of C3 
(A, B) and C5 (C, D) comple-
ment proteins (green) with the 
islet hormones insulin (a–c), 
glucagon (d–f) and somatostatin 
(g–i) (red) in mouse (A, C) and 
human (B, D) islets. Nuclei 
have been counterstained with 
DAPI (blue). C3 and C5 were 
also expressed by exocrine 
cells in both mouse and human 
pancreas. E, G C3 co-localises 
in mouse and human islets with 
insulin, glucagon and somato-
statin, indicating expression of 
C3 in β-, α- and δ-cells. F, H 
C5 co-localises in mouse and 
human islets primarily with 
insulin, indicating predominant 
expression of C5 in β-cells
(A) (B)
(C) (D)
(E) (F)
(G) (H)
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Effects of C3aR and C5aR1 agonists on islet cell 
intracellular  Ca2+ levels
C3a and C5a are reported to elevate  [Ca2+]i in neutrophils 
[26, 27] so Fura-2-loaded mouse islets were used to identify 
whether islet C3aR and C5aR1 were coupled to increases 
in  [Ca2+]i. Agonists at C3aR (1 μM sc-214644) and C5aR1 
(1 μM 65121-ANA) caused rapid, sustained elevations in 
 [Ca2+]i at 20 mM glucose, which were reversible follow-
ing removal of the activating ligand, and the islet cells also 
responded to 500μM carbachol with the expected increase 
in  [Ca2+]i (Fig. 8).
Effects of C3aR and C5aR1 activation on islet apoptosis
Mouse and human islet caspase 3/7 activation, induced 
either by a cocktail of pro-apoptotic cytokines or by the 
saturated fatty acid palmitate, was significantly inhibited 
in the presence of C3aR and C5aR1 agonists (Fig. 9a–d). 
In human islets, the protection against palmitate-induced 
Fig. 3  C3aR and C5aR1 beta-
arrestin recruitment. a, b Con-
centration–response curves for 
high affinity C3aR (sc-214644) 
and C5aR1 (65121-ANA) 
agonists. c Intact C3 (solid line) 
induced concentration-depend-
ent activation of C3aR, whereas 
intact C5 (dotted line) had no 
effect. d Intact C5 induced 
concentration-dependent activa-
tion of C5aR1 (dotted line), and 
very weak activation was also 
observed with intact C3 (solid 
line)
(A) (B)
(C) (D)
Fig. 4  Islet-derived C3aR and 
C5aR1 activating factors. A 
glucose-dependent increase in 
beta-arrestin activity of C3aR 
(a) and C5aR1 (b) was observed 
in the presence of mouse islet-
conditioned media, suggesting 
that C3aR and C5aR1-activating 
factors are released in a glucose-
dependent manner from mouse 
islets. *p < 0.05, **p < 0.01, 
***p < 0.001, n = 3–6
(A)
(B)
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apoptosis by C3aR and C5aR1 activation was of a similar 
magnitude to that of 20 nM Exendin-4, an established anti-
apoptotic GPCR agonist in islets.
Discussion
The complement system consists of a tightly regulated net-
work of proteins that play important roles in host defence 
and inflammation. Intact C3 and C5 proteins and the cleaved 
C3a and C5a peptides are reported to act as mediators of 
inflammation-induced insulin resistance [9–12], but a ben-
eficial effect of complement factor D, a protease required 
for the generation of the C3 convertase, on β-cell function 
has been demonstrated [14]. Here, we have demonstrated 
C3 and C5 mRNA and protein expression by human and 
mouse islets, and that C3aR and C5aR1 activation promotes 
improvements in islet secretory function and viability.
Our qPCR analysis showed that genes for all complement 
components studied were present in mouse and human islet 
preparations. The identification of C3 mRNA in ICR mouse 
islets, at levels at least tenfold higher than those of C5, is in 
contrast to an earlier report that C3 mRNA is not expressed 
by islets isolated from C57 BL/6 mice [14]. The reasons 
for this discrepancy are not immediately obvious, but may 
reflect strain-dependent differences in complement protein 
expression by the pancreas, as we have recently reported for 
GPCR expression [28]. Our quantification of C3 mRNA in 
islets from human donors, at levels similar to those identified 
in ICR mouse islets, also points to its expression by islet 
cells. However, since mRNA quantifications do not always 
reflect relative protein expression levels nor importance in 
a particular tissue [29], we used fluorescence immunohis-
tochemistry to confirm expression of C3 and C5 in mouse 
and human islets, consistent with a functional role for these 
complement proteins in islet physiology. We also observed 
expression of complement proteins by exocrine cells, sup-
porting an earlier report of local production of C3 in the 
exocrine pancreas where it was implicated in complement-
mediated immunological protection [30]. We attempted to 
identify C3aR and C5aR1 expression by mouse and human 
islets, but we were unable to demonstrate specific staining 
with commercially available antibodies, consistent with low 
detection levels obtained by qPCR. Nonetheless, the func-
tional effects of the C3aR and C5aR1 activation described in 
this paper indirectly indicate the presence of these receptors 
on islet cells.
Traditional assays for GPCRs identify the functional 
responses elicited by receptor activation and downstream 
signalling through heterotrimeric G proteins. Beta-arrestin 
recruitment, which occurs independently of G-protein cou-
pling, is a powerful screening platform for direct measure-
ment of GPCR activity by detecting interaction of beta-
arrestin with the activated GPCR [31]. We took advantage 
of C3aR and C5aR1 beta-arrestin assays to demonstrate that 
islets secreted factors that stimulated C3aR and C5aR1-
mediated beta-arrestin recruitment in a glucose-dependent 
manner. To the best of our knowledge, this is the first time 
Fig. 5  Effects of complement 
components on static insulin 
secretion in islets. Effects 
of C3aR agonist sc-214644, 
intact C3 and C3aR antagonist 
SB 290157 (a, c) and C5aR1 
agonist 65121-ANA, intact C5 
and C5aR1 antagonist PMX 205 
(b, d) on glucose-stimulated 
insulin secretion from mouse 
(a, b) and human (c, d) islets. 
C3aR (1 µM, sc-214644) and 
C5aR1 (1 µM, 65121-ANA) 
agonists potentiated glucose-
induced insulin secretion from 
mouse and human islets, with 
similar stimulatory effects 
observed in islets incubated 
with 100 nM intact C3 and C5. 
Stimulation by intact C3 and C5 
was blocked by SB 290157 and 
PMX 205, which also inhibited 
glucose-induced insulin secre-
tion. *p < 0.05, **p < 0.01, 
***p < 0.001, n = 15
(A) (B)
(C) (D)
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Fig. 6  Effects of complement 
components on time-resolved 
insulin secretion from human 
islets. Addition of sc-214644 (a) 
or 65121-ANA (b) to a physi-
ological buffer significantly 
increased glucose-stimulated 
insulin secretion from human 
islets, whereas addition of SB 
290157 or PMX 205 in the 
presence of the corresponding 
agonist significantly decreased 
insulin secretion. ***p < 0.001, 
n = 4
(A)
(B)
Fig. 7  ATP generation 
stimulated by complement 
components in mouse islets. 
sc-214644, 65121-ANA and 
intact C3 and C5 significantly 
stimulated ATP production 
in mouse islets, whereas SB 
290157 and PMX 205 signifi-
cantly reduced glucose-induced 
ATP generation. *p < 0.05, 
***p < 0.001, n = 12
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that a cell-based beta-arrestin assay has been used to detect 
GPCR-activating factors released from islets. The specificity 
of these assays relies on the use of cell lines in which a small 
enzyme fragment is fused to the GPCR under investigation 
and a larger enzyme fragment is fused to beta-arrestin. When 
the receptor is activated, it binds to beta-arrestin and both 
enzyme fragments combine, resulting in enzyme activity 
that is detected by chemiluminescence. The beta-arrestin 
assays were also used to demonstrate that C3aR and C5aR1 
agonists caused concentration-dependent activation of the 
receptors, as expected. Intact C3 and C5 were included in 
the beta-arrestin assays as negative controls since they are 
not thought to be agonists of the complement receptors. 
However, we unexpectedly found that exogenous intact C3 
and C5 proteins stimulated low-level beta-arrestin recruit-
ment, indicative of C3aR and C5aR1 activation, respectively. 
Fig. 8  Stimulatory effects of C3aR and C5aR1 agonists on intracel-
lular calcium in mouse islets. C3aR (1  µM, sc-214644) and C5aR1 
(1  µM, 65121-ANA) agonists reversibly elevated  [Ca2+]i in mouse 
islet cells. 500  µM carbachol was used as a positive control. Mean 
changes in  [Ca2+]i levels in six individual cells, expressed as the 
340 nm/380 nm fluorescence ratio, are shown in black and the SEMs 
for each time point are shown in grey
Fig. 9  Effects of C3aR and 
C5aR1 agonists on mouse and 
human islet apoptosis. Caspase 
3/7 activities in mouse (a, b) 
and human (c, d) islets were 
induced by a cocktail of pro-
apoptotic cytokines (a, c) or by 
palmitate (b, d). sc-214644 and 
65121-ANA protected against 
apoptosis in both mouse and 
human islets. 20 nM Exendin-4 
was included as reference treat-
ment for the human islet experi-
ments (c, d). ***p < 0.001, 
n = 6
(A) (B)
(C) (D)
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These data suggest that there was local production of the 
active C3a and C5a peptides in these experiments, either 
through expression of the corresponding convertases by the 
reporter U2OS and CHO-K1 cells or by proteases in the 
serum-supplemented medium, in accordance with published 
studies of spontaneous C3 activation in plasma [32, 33]. It 
cannot, however, be ruled out that intact C3 and C5 can act 
as low-affinity, direct activators of C3aR and C5aR1.
Plasma levels of C3 are positively associated with insulin 
secretion in non-diabetic human subjects, which may sug-
gest that C3 is a contributor to insulin release [34]. Stimu-
latory effects on insulin secretion from mouse islets have 
been reported for acylation stimulating protein, a desArg 
derivative of C3a [35] and C3a itself, effects mediated by 
activation of islet C3aR [14]. Building on these earlier stud-
ies we have now observed that C3aR and C5aR1 agonists 
potentiated glucose-stimulated insulin secretion from both 
human and mouse islets, consistent with C3aR and C5aR1 
being key positive regulators of insulin secretion. Similar 
stimulatory effects were observed with intact C3 and C5, 
suggesting that they are cleaved to the active peptides by 
their convertases, or that the proteins may themselves act as 
low-affinity direct activators of their corresponding recep-
tors. Intact C3 and C5 were used for these experiments at 
100 nM, which is lower than circulating concentrations of 
these complement components [36]. However, we have 
shown here that there is local production of these proteins 
by islets and it is possible that autocrine or paracrine signal-
ling within islets occurs at lower concentrations than are 
reached during inflammation-mediated elevations in circu-
lating intact C3 and C5. Antagonists of C3aR (SB 290157) 
and C5aR1 (PMX 205 and W 54011) induced concentration-
dependent inhibition of glucose-stimulated insulin secretion, 
even in the absence of exogenously added C3aR and C5aR1 
agonists. This in vitro inhibition of insulin secretion sug-
gests that the endogenous islet-derived complement C3/a 
and C5/a peptides normally act in an auto/paracrine manner 
when released from islets to promote insulin release. These 
results are also in agreement with an earlier study in which 
antagonism of C3aR in db/db mice with SB 290157 inhib-
ited adipsin-mediated improvements in glucose tolerance 
and insulin secretion [14].
It is well established that glucose metabolism and ATP 
synthesis in β-cells is essential for  Ca2+ influx and insu-
lin granule exocytosis [37]. C3aR and C5aR1 are pertus-
sis toxin-sensitive GPCRs [38, 39], suggesting signalling 
through Gi that does not fit with their stimulatory effects on 
insulin release. However, it has been reported that C3aR acti-
vation can elevate  [Ca2+]i [14], perhaps via Gq coupling. We 
found that C3aR and C5aR1 agonists significantly increased 
 [Ca2+]i in mouse islets and they also led to significant ele-
vations in ATP generation, as did intact C3 or C5. These 
observations suggest that islet C3aR- and C5aR1-mediated 
elevations in  [Ca2+]i may lead to increased mitochondrial 
 [Ca2+] [40], promoting Krebs cycle activity and leading to 
enhanced ATP content. The C3aR and C5aR1 antagonists 
significantly inhibited glucose-stimulated ATP production, 
which may have been responsible, at least in part, for their 
inhibitory effects of glucose-stimulated insulin secretion.
A major feature of T2D is the progressive loss of β-cell 
mass, reflecting a shift from islet quiescence/proliferation 
to β-cell apoptosis [1]. An anti-apoptotic effect of a C5aR1 
agonist in neurons has been reported [41], an unexpected 
function for an anaphylatoxin. Further evidence of a protec-
tive role for complement peptides is provided by a recent 
study in which C3a and C5a peptides reduced apoptosis of 
myeloid and lymphoid cells [42]. In the current study, acti-
vation of mouse and human islet C3aR and C5aR1 led to 
a robust reduction in apoptosis that had been induced by a 
cytokine cocktail or the saturated fatty acid palmitate. This 
apparent paradoxical effect of complement cascade com-
ponents may be a protective mechanism to maintain β-cell 
mass in conditions such as obesity, which normally exerts 
increased stress on the β-cell population. These findings also 
support previous proposals of a beneficial role of comple-
ment proteins on tissue remodelling [43].
In summary, our data reveal that C3 and C5 complement 
proteins and their receptors are expressed by human and 
mouse islets, and that islets secrete complement receptor 
activating ligands in a glucose-dependent manner. Activa-
tion of islet C3aR and C5aR1 results in increased intracellu-
lar calcium and ATP levels, potentiation of glucose-induced 
insulin secretion and protection against apoptosis. These 
observations demonstrate a functional link between acti-
vation of components of the innate immune and improved 
human and mouse β-cell function, suggesting that comple-
ment peptides exert direct stimulatory effects at islet β-cells 
that could compensate for their induction of peripheral insu-
lin resistance.
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